We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ALX Oncology Holdings Inc (ALXO) USD0.001

Sell:$11.17 Buy:$11.18 Change: $0.45 (3.94%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$11.17
Buy:$11.18
Change: $0.45 (3.94%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$11.17
Buy:$11.18
Change: $0.45 (3.94%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Contact details

Address:
323 Allerton Avenue
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 4667125
Website:
https://alxoncology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALXO
ISIN:
US00166B1052
Market cap:
$561.20 million
Shares in issue:
50.15 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jaume Pons
    President, Chief Scientific Officer
  • Jason Lettmann
    Chief Executive Officer, Director
  • Peter Garcia
    Chief Financial Officer
  • Shelly Pinto
    Chief Accounting Officer, Vice President - Finance
  • Sophia Randolph
    Chief Medical Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.